| 1 |
Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022;16:721-35. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
|
| 2 |
Vasile Balaban D, Jinga M. Apheresis in Inflammatory Bowel Disease: Current Evidence. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.93605] [Reference Citation Analysis]
|
| 3 |
Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
|
| 4 |
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 44.5] [Reference Citation Analysis]
|
| 5 |
Schuster IP, Klyachman L, Rajapakse R, Monzur F. New Developments in the Management of Crohn’s Disease. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_4] [Reference Citation Analysis]
|
| 6 |
Nishise S, Takeda Y, Abe Y, Sasaki Y, Saitoh S, Nara H, Asao H, Ueno Y. Physiological heating augments the anti-inflammatory reactions during granulocyte/monocyte apheresis: A in vitro study. Ther Apher Dial 2021;25:671-80. [PMID: 33067913 DOI: 10.1111/1744-9987.13600] [Reference Citation Analysis]
|
| 7 |
Shibuya T, Haga K, Saeki M, Haraikawa M, Tsuchihashi H, Okahara K, Nomura O, Fukushima H, Murakami T, Ishikawa D, Ikeda S, Nagahara A. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis. J Clin Apher 2020;35:488-92. [PMID: 32767842 DOI: 10.1002/jca.21821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 8 |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 9 |
Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V, Gupta YK, Kaur K. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020;18:184-91. [PMID: 32092799 DOI: 10.5217/ir.2019.00094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 10 |
Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 12 |
Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Eberhardson M, Finkel Y. Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New-onset Inflammatory Colitis. J Pediatr Gastroenterol Nutr 2018;66:e103-7. [PMID: 28891831 DOI: 10.1097/MPG.0000000000001735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 13 |
Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018;53:305-53. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 281] [Cited by in F6Publishing: 281] [Article Influence: 56.2] [Reference Citation Analysis]
|
| 14 |
Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr 2018;66:84-9. [PMID: 28604509 DOI: 10.1097/MPG.0000000000001641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 15 |
Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol 2017;11:749-58. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Nishise S, Takeda Y, Abe Y, Sasaki Y, Nara H, Asao H, Ueno Y. Effect of Temperature on Granulocyte and Monocyte Adsorption to Cellulose Acetate Beads: Temperature Affects Leukocyte Adsorption. Ther Apher Dial 2017;21:248-54. [DOI: 10.1111/1744-9987.12558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Gerçeker E, Yüceyar H, Kasap E, Demirci U, Ekti BC, Aydoğdu İ, Miskioğlu M. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci 2017;56:421-6. [PMID: 28454883 DOI: 10.1016/j.transci.2017.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 18 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 19 |
Mitrová K. News in treatment of inflammatory bowel diseases in children. Pediatr pro Praxi 2016;17:344-347. [DOI: 10.36290/ped.2016.076] [Reference Citation Analysis]
|
| 20 |
Nishise S, Abe Y, Nomura E, Sato T, Sasaki Y, Iwano D, Yoshizawa K, Yagi M, Sakuta K, Ueno Y. Effect of Cellulose Acetate Beads on Interleukin-23 Release: Effect of CA Beads on IL-23 Release. Ther Apher Dial 2016;20:354-9. [DOI: 10.1111/1744-9987.12466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 21 |
Edfors K, Ståhlberg D, Söderman C. Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease. Ther Apher Dial 2016;20:79-85. [PMID: 26841133 DOI: 10.1111/1744-9987.12336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 22 |
Kuwaki K, Mitsuyama K, Kaida H, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Fukunaga S, Abe T, Tsuruta O. A longitudinal study of FDG-PET in Crohn disease patients receiving granulocyte/monocyte apheresis therapy. Cytotherapy. 2016;18:291-299. [PMID: 26700210 DOI: 10.1016/j.jcyt.2015.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 23 |
Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, Nakagawa T, Fukuchi T, Motoya S, Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S, Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol. 2015;15:163. [PMID: 26585569 DOI: 10.1186/s12876-015-0390-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 24 |
Nishise S, Abe Y, Nomura E, Sato T, Sasaki Y, Iwano D, Yagi M, Sakuta K, Shibuya R, Mizumoto N, Kanno N, Ueno Y. Effect of Cellulose Acetate Beads on the Release of Transforming Growth Factor-β: Effect of CA Beads on TGF-β Release. Ther Apher Dial 2015;19:330-5. [DOI: 10.1111/1744-9987.12341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 26 |
Yuksel M, Saygili F, Coskun O, Suna N, Kaplan M, Kuzu UB, Kilic ZMY, Ozin YO, Kayacetin E. Treatment of Crohn’s disease and familial Mediterranean fever by leukopheresis: Single shot for two targets. World J Gastroenterol 2015; 21(13): 4078-4081 [PMID: 25852296 DOI: 10.3748/wjg.v21.i13.4078] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 27 |
Fowler S, Jones J, Hull PR, Ghosh S. Extracorporeal photopheresis for the treatment of Crohn's disease. Transfusion and Apheresis Science 2015;52:183-6. [DOI: 10.1016/j.transci.2015.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 28 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 29 |
Fukuchi T, Nakase H, Ubukata S, Matsuura M, Yoshino T, Toyonaga T, Shimazu K, Koga H, Yamashita H, Ito D. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease. BMC Gastroenterol. 2013;13:124. [PMID: 25015328 DOI: 10.1186/1471-230x-14-124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 30 |
Nishise S, Abe Y, Nomura E, Sato T, Sasaki Y, Iwano D, Yoshizawa K, Yagi M, Nishise Y, Ueno Y. Relationship Between Tumor Necrosis Factor-α Release and Granulocyte and Monocyte Adsorption to Cellulose Acetate Beads: TNF-α Release by Leukocyte Adsorption. Ther Apher Dial 2014;18:252-7. [DOI: 10.1111/1744-9987.12212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 31 |
Itoh Y, Tsukamoto M. Cytapheresis. The Concise Manual of Apheresis Therapy 2014. [DOI: 10.1007/978-4-431-54412-8_11] [Reference Citation Analysis]
|
| 32 |
Takagi T, Uchiyama K, Naito Y. Oxidative Stress in Inflammatory Bowel Disease. Studies on Pediatric Disorders 2014. [DOI: 10.1007/978-1-4939-0679-6_18] [Reference Citation Analysis]
|
| 33 |
Nagase K, Fukuanga K, Yokoyama Y, Kamikozuru K, Miwa H, Nakamura S. Questionnaire Based Assessment of Patients' Acceptability of Leukocytapheresis for the Treatment of Inflammatory Bowel Disease: Patients' Acceptability of Leukocytapheresis. Ther Apher Dial 2013;17:490-7. [DOI: 10.1111/1744-9987.12115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 34 |
Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013;62:1288-94. [PMID: 22760005 DOI: 10.1136/gutjnl-2011-300995] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 35 |
Toya Y, Chiba T, Mizutani T, Sato K, Kasugai S, Matsuda N, Orikasa S, Shibata S, Abiko Y, Akasaka R, Yokoyama N, Oana S, Hirota S, Endo M, Suzuki K. The effect of granulocyte and monocyte adsorptive apheresis on serum cytokine levels in patients with ulcerative colitis. Cytokine 2013;62:146-50. [PMID: 23465691 DOI: 10.1016/j.cyto.2013.01.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 36 |
Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T; Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol 2013;48:31-72. [PMID: 23090001 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 37 |
Ozeki K, Tanida S, Mizoshita T, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn’s Disease. Case Rep Gastroenterol. 2012;6:765-771. [PMID: 23341799 DOI: 10.1159/000346312] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 38 |
Philippe D, Brahmbhatt V, Foata F, Saudan Y, Serrant P, Blum S, Benyacoub J, Vidal K. Anti-inflammatory effects of Lacto-Wolfberry in a mouse model of experimental colitis. World J Gastroenterol 2012; 18(38): 5351-5359 [PMID: 23082051 DOI: 10.3748/wjg.v18.i38.5351] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 39 |
Nishise S, Sato T, Sasaki Y, Nagino K, Iwano D, Yaoita T, Yoshizawa K, Nishise Y, Takeda H. Production of Interleukin-10 by Combining a Granulocyte and Monocyte Adsorption Carrier With Ulinastatin: IL-10 Production by Ulinastatin. Therapeutic Apheresis and Dialysis 2012;16:449-55. [DOI: 10.1111/j.1744-9987.2012.01110.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 40 |
Kato S, Hosomi E, Amano F, Kobayashi T, Kani K, Yamamoto R, Ogawa T, Matsuda A, Sato Y, Izaki S, Mitarai T, Yakabi K. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis 2012;6:787-91. [PMID: 22386738 DOI: 10.1016/j.crohns.2012.02.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 41 |
Mizoshita T, Tanida S, Kusumoto S, Ozeki K, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol 2012;5:302-6. [PMID: 26182398 DOI: 10.1007/s12328-012-0314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 42 |
Fukunaga K, Matsumoto T. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:997-1003. [PMID: 22414250 DOI: 10.1111/j.1440-1746.2012.07119.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 43 |
Itagaki M, Saruta M, Iinuma T, Arihiro S, Kato T, Tajiri H. Infliximab- and immunosuppressant-resistant Crohn's disease successfully treated with adsorptive granulocyte apheresis combined with prednisolone. Case Rep Gastroenterol 2012;6:118-23. [PMID: 22761605 DOI: 10.1159/000334428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 44 |
Clerici M, Cassinotti A, Onida F, Trabattoni D, Annaloro C, Della Volpe A, Rainone V, Lissoni F, Duca P, Sampietro G, Fociani P, Vago G, Foschi D, Ardizzone S, Deliliers GL, Porro GB. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis 2011;43:946-52. [PMID: 21907652 DOI: 10.1016/j.dld.2011.07.021] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 45 |
Abe T, Kato K, Fujioka T, Akizawa T. The blood compatibilities of blood purification membranes and other materials developed in Japan. Int J Biomater 2011;2011:375390. [PMID: 21969830 DOI: 10.1155/2011/375390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 46 |
Nishise S, Takeda H, Orii T, Sato T, Sasaki Y, Nishise Y, Kawata S. Evaluation of the Effect of Ulinastatin on the Production of Macrophage Colony-Stimulating Factor In Vitro for Potential Combination Therapy with Leukocyte Adsorption: M-CSF Production by Ulinastatin. Therapeutic Apheresis and Dialysis 2011;15:379-84. [DOI: 10.1111/j.1744-9987.2011.00967.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 47 |
Nagase K, Fukunaga K, Kashiwamura S, Kono T, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Miwa H, Matsumoto T. Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte Apheresis in Patients with Drug Refractory Crohn's Disease: Immunoregulatory Effects of GMA in CD. Therapeutic Apheresis and Dialysis 2011;15:367-73. [DOI: 10.1111/j.1744-9987.2011.00970.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 48 |
Moribata K, Kato J, Iimura S, Yoshida S, Shingaki N, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Tamai H, Ichinose M. Mucosal healing of esophageal involvement of Crohn's disease with granulocyte/monocyte adsorption. J Clin Apher 2011;26:225-7. [PMID: 21786316 DOI: 10.1002/jca.20295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 49 |
Takagi T, Naito Y, Uchiyama K, Suzuki T, Hirata I, Mizushima K, Tsuboi H, Hayashi N, Handa O, Ishikawa T, Yagi N, Kokura S, Ichikawa H, Yoshikawa T. Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an anti-inflammatory effect on dextran sulfate sodium-induced colitis in mice. Dig Dis Sci 2011;56:1663-71. [PMID: 21086163 DOI: 10.1007/s10620-010-1484-y] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 50 |
Fukunaga K, Yokoyama Y, Kamikozuru K, Yoshida K, Kikuyama R, Nagase K, Nakamura S, Takei Y, Miwa H, Matsumoto T. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. J Clin Apher. 2010;25:226-228. [PMID: 20544712 DOI: 10.1002/jca.20242] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 51 |
Hisamatsu T, Hibi T. 6. Progress in Management of Crohn's Disease. J Jpn Soc Intern Med 2011;100:85-95. [DOI: 10.2169/naika.100.85] [Reference Citation Analysis]
|
| 52 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 53 |
Kondo J, Iijima H, Abe T, Komori M, Hiyama S, Ito T, Nakama A, Tominaga K, Kubo M, Suzuki K, Iwanaga Y, Ebara R, Takeda A, Tsuji S, Nishida T, Tsutsui S, Tsujii M, Hayashi N. Roles of double-balloon endoscopy in the diagnosis and treatment of Crohn's disease: a multicenter experience. J Gastroenterol 2010;45:713-20. [PMID: 20174832 DOI: 10.1007/s00535-010-0216-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 54 |
Suzuki Y. An Update on the Treatment of Crohn's Disease. Journal of Japan Society of Coloproctology 2010;63:863-868. [DOI: 10.3862/jcoloproctology.63.863] [Reference Citation Analysis]
|
| 55 |
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-5. [PMID: 19724269 DOI: 10.1038/ajg.2009.453] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 56 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 57 |
Tozawa K, Fukunaga K, Kamikozuru K, Ohnishi K, Hida N, Ohda Y, Kusaka T, Yoshida K, Jinno Y, Nagase K, Nakamura S, Miwa H, Matsumoto T. Hyperthermic stimulation of blood increases the immunological effects of granulocyte and monocyte adsorption in vitro: Relevance to extracorporeal immunomodulation. Transfusion and Apheresis Science 2008;39:129-35. [DOI: 10.1016/j.transci.2008.07.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 58 |
Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 2008;14:1068-83. [PMID: 18425802 DOI: 10.1002/ibd.20448] [Cited by in Crossref: 166] [Cited by in F6Publishing: 165] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 59 |
Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 60 |
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. [PMID: 18382085 DOI: 10.1159/000122473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 61 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 62 |
Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol 2008;43:51-6. [PMID: 18297436 DOI: 10.1007/s00535-007-2129-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 63 |
Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr 2008;46:386-91. [PMID: 18367949 DOI: 10.1097/MPG.0b013e31815604e5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 64 |
Matsumoto T, Fukunaga K, Kamikozuru K, Tozawa K, Yokoyama Y, Kusaka T, Onishi K, Miwa H, Nakamura S. Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease. Transfus Med Hemother. 2008;35:18-23. [PMID: 21547106 DOI: 10.1159/000111763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 65 |
Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:874-88. [PMID: 18090155 DOI: 10.1097/MCG.0b013e3180479435] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 66 |
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 67 |
Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol 2007;42:787-98. [PMID: 17940831 DOI: 10.1007/s00535-007-2096-y] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 68 |
Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007;39:435-7. [PMID: 17379590 DOI: 10.1016/j.dld.2007.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 69 |
Hibi T. Apheresis. Immunoregulation in Inflammatory Bowel Diseases — Current Understanding and Innovation. [DOI: 10.1007/978-1-4020-5889-9_21] [Reference Citation Analysis]
|
| 70 |
Asakura H, Suzuki K, Honma T. Recent advances in basic and clinical aspects of inflammatory bowel disease: Which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease? World J Gastroenterol 2007; 13(15): 2145-2149 [PMID: 17465491 DOI: 10.3748/wjg.v13.i15.2145] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 71 |
Matsumoto T, Fukunaga K, Kusaka T, Onishi K, Yokoyama Y, Ohda Y, Jinno Y, Hida N, Yoshida K. Depleting phagocytes. Falk Symposium. [DOI: 10.1007/978-1-4020-5702-1_34] [Reference Citation Analysis]
|
| 72 |
Emmrich J. Leucocytapheresis. Falk Symposium. [DOI: 10.1007/1-4020-4316-3_24] [Reference Citation Analysis]
|
| 73 |
Millward PA, Bandarenko N, Brecher ME. Therapeutic Apheresis: Basic Principles and Practical Aspects. Blood Banking and Transfusion Medicine 2007. [DOI: 10.1016/b978-0-443-06981-9.50059-4] [Reference Citation Analysis]
|
| 74 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 75 |
Balint B, Ostojic G, Pavlovic M, Hrvacevic R, Pavlovic M, Tukic L, Radovic M. Cytapheresis in the treatment of cell-affected blood disorders and abnormalities. Transfusion and Apheresis Science 2006;35:25-31. [DOI: 10.1016/j.transci.2006.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 76 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 77 |
González-lara V, Marín-jiménez I. Nuevas perspectivas en aféresis terapéutica en la enfermedad inflamatoria intestinal crónica. Diálisis y Trasplante 2006;27:46-58. [DOI: 10.1016/s1886-2845(06)71012-8] [Reference Citation Analysis]
|
| 78 |
Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 79 |
Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S15-21. [PMID: 16378006 DOI: 10.1097/01.mib.0000195387.26892.22] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 80 |
Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2005;7:485-91. [DOI: 10.1007/s11894-005-0080-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 81 |
Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Rev Gastroenterol Hepatol 2005;2:200-1. [DOI: 10.1038/ncpgasthep0168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
